Welcome to LookChem.com Sign In|Join Free

CAS

  • or

1218-34-4

Post Buying Request

1218-34-4 Suppliers

Recommended suppliersmore

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

1218-34-4 Usage

Chemical Properties

solid

Uses

N-Acetyl-L-Tryptophan, is a derivative of L-Tryptophan (T947210), that can be used as competitive inhibitor to identify and characterize tryptophanases. It can also be used as an NK1 tachykinin receptor antagonist, that may help to develop a novel therapeutic intervention for the treatment of reperfusion injury in acute ischemic stroke.

Definition

ChEBI: A N-acetyl-L-amino acid that is the N-acetyl derivative of L-tryptophan.

Safety Profile

Moderately toxic by some routes. An experimental teratogen. Other experimental reproductive effects. When heated to decomposition it emits toxic fumes of NOX,.

Check Digit Verification of cas no

The CAS Registry Mumber 1218-34-4 includes 7 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 4 digits, 1,2,1 and 8 respectively; the second part has 2 digits, 3 and 4 respectively.
Calculate Digit Verification of CAS Registry Number 1218-34:
(6*1)+(5*2)+(4*1)+(3*8)+(2*3)+(1*4)=54
54 % 10 = 4
So 1218-34-4 is a valid CAS Registry Number.
InChI:InChI=1/C13H14N2O3/c1-8(16)15-12(13(17)18)6-9-7-14-11-5-3-2-4-10(9)11/h2-5,7,12,14H,6H2,1H3,(H,15,16)(H,17,18)/t12-/m0/s1

1218-34-4 Well-known Company Product Price

  • Brand
  • (Code)Product description
  • CAS number
  • Packaging
  • Price
  • Detail
  • TCI America

  • (A0121)  N-Acetyl-L-tryptophan  >98.0%(HPLC)

  • 1218-34-4

  • 1g

  • 160.00CNY

  • Detail
  • TCI America

  • (A0121)  N-Acetyl-L-tryptophan  >98.0%(HPLC)

  • 1218-34-4

  • 25g

  • 1,190.00CNY

  • Detail
  • Sigma-Aldrich

  • (PHR1177)  N-Acetyl-L-tryptophan  pharmaceutical secondary standard; traceable to USP

  • 1218-34-4

  • PHR1177-500MG

  • 1,024.57CNY

  • Detail
  • Sigma-Aldrich

  • (A0208000)  N-Acetyltryptophan  European Pharmacopoeia (EP) Reference Standard

  • 1218-34-4

  • A0208000

  • 1,880.19CNY

  • Detail
  • USP

  • (1700523)  Tryptophan Related Compound B  United States Pharmacopeia (USP) Reference Standard

  • 1218-34-4

  • 1700523-25MG

  • 13,501.80CNY

  • Detail

1218-34-4SDS

SAFETY DATA SHEETS

According to Globally Harmonized System of Classification and Labelling of Chemicals (GHS) - Sixth revised edition

Version: 1.0

Creation Date: Aug 10, 2017

Revision Date: Aug 10, 2017

1.Identification

1.1 GHS Product identifier

Product name N-acetyl-L-tryptophan

1.2 Other means of identification

Product number -
Other names L-Tryptophan, N-acetyl-

1.3 Recommended use of the chemical and restrictions on use

Identified uses For industry use only.
Uses advised against no data available

1.4 Supplier's details

1.5 Emergency phone number

Emergency phone number -
Service hours Monday to Friday, 9am-5pm (Standard time zone: UTC/GMT +8 hours).

More Details:1218-34-4 SDS

1218-34-4Synthetic route

N-acetyltryptophan methyl ester
2824-57-9, 16108-06-8, 36060-94-3

N-acetyltryptophan methyl ester

A

N-AcTrp
1218-34-4

N-AcTrp

Conditions
ConditionsYield
With sodium hydroxide; phosphate buffer; pronase EC 3.4.24.4 In tetrahydrofuran Ambient temperature;A 99%
B 99%
With methanol; water; α-chymotrypsin bei pH 7.8;
acetyl chloride
75-36-5

acetyl chloride

L-Tryptophan
73-22-3

L-Tryptophan

N-AcTrp
1218-34-4

N-AcTrp

Conditions
ConditionsYield
With sodium hydroxide In acetone at 20℃; pH=> 10;80%
thioacetic acid
507-09-5

thioacetic acid

L-Tryptophan
73-22-3

L-Tryptophan

N-AcTrp
1218-34-4

N-AcTrp

Conditions
ConditionsYield
Stage #1: tiolacetic acid With caesium carbonate In N,N-dimethyl-formamide at 20℃; for 0.0833333h;
Stage #2: L-Tryptophan With 2,4-Dinitrofluorobenzene In N,N-dimethyl-formamide at 20℃; for 3h;
76%
acetic anhydride
108-24-7

acetic anhydride

L-Tryptophan
73-22-3

L-Tryptophan

N-AcTrp
1218-34-4

N-AcTrp

Conditions
ConditionsYield
With sodium In water for 2h;73%
Stage #1: L-Tryptophan With sodium hydroxide In water for 0.5h;
Stage #2: acetic anhydride In water at 20℃;
71.8%
With sodium hydroxide; water
N-acetyl-L-tryptophane ethyl ester
2382-80-1

N-acetyl-L-tryptophane ethyl ester

N-AcTrp
1218-34-4

N-AcTrp

Conditions
ConditionsYield
With ammonium bicarbonate; water In dichloromethane for 21h; α-chymotrypsin;45%
With α-chymotrypsin In phosphate buffer at 25℃; pH=7.8; Kinetics; Further Variations:; Reaction partners; Catalysts; Hydrolysis; Enzymatic reaction;
acetyltryptophan ethylester
42717-06-6

acetyltryptophan ethylester

A

N-AcTrp
1218-34-4

N-AcTrp

B

N-acetyl-D-tryptophan
2280-01-5

N-acetyl-D-tryptophan

C

N-acetyl-D-tryptophan ethyl ester
92520-19-9

N-acetyl-D-tryptophan ethyl ester

Conditions
ConditionsYield
With water In ethanol at 25℃; for 24h; Microbiological reaction; optical yield given as %ee; enantioselective reaction;A n/a
B n/a
C 40%
tetrachloromethane
56-23-5

tetrachloromethane

acetic anhydride
108-24-7

acetic anhydride

L-Tryptophan
73-22-3

L-Tryptophan

N-AcTrp
1218-34-4

N-AcTrp

N-acetyl-DL-tryptophan
1218-34-4, 87-32-1

N-acetyl-DL-tryptophan

N-AcTrp
1218-34-4

N-AcTrp

Conditions
ConditionsYield
With (S)-1-phenyl-ethylamine
With (1S,2S)-2-amino-1-(4-nitrophenyl)propane-1,3-diol
With (1S,2S)-(+)-thiomicamine
N-acetyl-DL-tryptophan
1218-34-4, 87-32-1

N-acetyl-DL-tryptophan

A

N-AcTrp
1218-34-4

N-AcTrp

B

N-acetyl-D-tryptophan
2280-01-5

N-acetyl-D-tryptophan

Conditions
ConditionsYield
With water bei der Einwirkung einer Amidase;
mit Hilfe von Amidase aus Penicillium vinaceum oder Aspergillus orizae;
mit Hilfe von Pseudomonas;
With water bei der Einwirkung einer Amidase;
(Z)-2-acetamido-3-(3-indolyl)-2-propenoic acid
70082-70-1

(Z)-2-acetamido-3-(3-indolyl)-2-propenoic acid

A

N-AcTrp
1218-34-4

N-AcTrp

B

N-acetyl-D-tryptophan
2280-01-5

N-acetyl-D-tryptophan

Conditions
ConditionsYield
With hydrogen; chloro(1,5-cyclooctadiene)rhodium(I) dimer; (-)-Diop In ethanol at 50℃; for 1.75h; Title compound not separated from byproducts;
With hydrogen; triethylamine; ClO4; (2S,4S)-MOD-BPPM In ethanol at 50℃; under 15200 Torr; for 20h; Title compound not separated from byproducts;
N-acetyl-L-triptophanyl-L-leucine amide
65356-77-6

N-acetyl-L-triptophanyl-L-leucine amide

B

N-AcTrp
1218-34-4

N-AcTrp

Conditions
ConditionsYield
With pH=7; α-chymotrypsin In water; ethyl acetate Equilibrium constant;
(S)-2-Acetylamino-5-(phenyl-hydrazono)-pentanoic acid methyl ester
85148-76-1

(S)-2-Acetylamino-5-(phenyl-hydrazono)-pentanoic acid methyl ester

N-AcTrp
1218-34-4

N-AcTrp

Conditions
ConditionsYield
With hydrogenchloride; sodium hydroxide 1.) reflux, 1 h;; Yield given. Multistep reaction;
4-nitrophenol acetate
830-03-5

4-nitrophenol acetate

L-Tryptophan
73-22-3

L-Tryptophan

A

4-nitro-phenol
100-02-7

4-nitro-phenol

B

N-AcTrp
1218-34-4

N-AcTrp

Conditions
ConditionsYield
β‐cyclodextrin In water; dimethyl sulfoxide at 25℃; Rate constant; Mechanism; various conditions;
Nα-acetyl-L-tryptophan-amide
2382-79-8

Nα-acetyl-L-tryptophan-amide

N-AcTrp
1218-34-4

N-AcTrp

Conditions
ConditionsYield
With Peptidamidase aus dem Flavedo von Orangen; water at 30℃; diff. Peptidamiden; diff. solvents; diff. pH;
With potassium phosphate buffer at 30℃; for 1h; amidase from Erwina carotovora; determination of relative rate of deamination;
With water at 30℃; Peptidamidase aus dem Flavedo von Orangen; Yield given;
With subtilisin-CLEC at 40℃; pH 7.5, phosphate buffer; Yield given;
N-acetyl-L-tryptophan methyl ester
2824-57-9, 16108-06-8, 36060-94-3

N-acetyl-L-tryptophan methyl ester

A

methanol
67-56-1

methanol

B

N-AcTrp
1218-34-4

N-AcTrp

Conditions
ConditionsYield
With water In dimethyl sulfoxide at 35℃; Rate constant; Equilibrium constant; pH 5.0, pH 7.1; influence of enzyme chymotrypsin; influence of BzPheal=Ala;
(S)-2-Acetylamino-4-cyano-butyric acid methyl ester
75161-70-5

(S)-2-Acetylamino-4-cyano-butyric acid methyl ester

N-AcTrp
1218-34-4

N-AcTrp

Conditions
ConditionsYield
Multi-step reaction with 3 steps
1: 88 percent / hydrogen / Raney-Ni deactivated with 3percent Pb / H2O; acetic acid
3: 1.) 0.1 N HCl; 2.) 1 N NaOH / 1.) reflux, 1 h;
View Scheme
methyl 2-acetamido-5-amino-5-oxopentanoate
56159-64-9

methyl 2-acetamido-5-amino-5-oxopentanoate

N-AcTrp
1218-34-4

N-AcTrp

Conditions
ConditionsYield
Multi-step reaction with 4 steps
1: 61 percent / p-TsCl / pyridine
2: 88 percent / hydrogen / Raney-Ni deactivated with 3percent Pb / H2O; acetic acid
4: 1.) 0.1 N HCl; 2.) 1 N NaOH / 1.) reflux, 1 h;
View Scheme
(2S,5R)-1-Acetyl-5-hydroxy-pyrrolidine-2-carboxylic acid methyl ester
85148-75-0

(2S,5R)-1-Acetyl-5-hydroxy-pyrrolidine-2-carboxylic acid methyl ester

N-AcTrp
1218-34-4

N-AcTrp

Conditions
ConditionsYield
Multi-step reaction with 2 steps
2: 1.) 0.1 N HCl; 2.) 1 N NaOH / 1.) reflux, 1 h;
View Scheme
DL-tryptophan ethyl ester hydrochloride
6519-67-1

DL-tryptophan ethyl ester hydrochloride

N-AcTrp
1218-34-4

N-AcTrp

Conditions
ConditionsYield
Multi-step reaction with 2 steps
1: aqueous K2CO3
2: α-chymotrypsin; methanol; water / bei pH 7.8
View Scheme
N-AcTrp
1218-34-4

N-AcTrp

Conditions
ConditionsYield
With acetic anhydride In water
Fmoc-Trp-OH
35737-15-6

Fmoc-Trp-OH

acetic acid
64-19-7

acetic acid

N-AcTrp
1218-34-4

N-AcTrp

Conditions
ConditionsYield
Stage #1: Fmoc-Trp-OH With dmap In N,N-dimethyl-formamide at 20℃; for 2h; Wang resin; Inert atmosphere;
Stage #2: acetic acid With ammonium bicarbonate In methanol at 20℃; for 3h;
Stage #3: With piperidine; trifluoroacetic acid In N,N-dimethyl-formamide at 20℃; Inert atmosphere;
N-Acetyl-N(1)-nitroso-L-tryptophan
53602-74-7

N-Acetyl-N(1)-nitroso-L-tryptophan

N-AcTrp
1218-34-4

N-AcTrp

Conditions
ConditionsYield
With L-Cysteine In aq. phosphate buffer at 37℃; for 1h; pH=7.4; Kinetics;
4-nitrophenol acetate
830-03-5

4-nitrophenol acetate

L-Tryptophan
73-22-3

L-Tryptophan

N-AcTrp
1218-34-4

N-AcTrp

Conditions
ConditionsYield
With sodium hydroxide In 1,4-dioxane; water at 24.84℃; pH=8.5 - 9; Kinetics;
benzyl bromide
100-39-0

benzyl bromide

N-AcTrp
1218-34-4

N-AcTrp

Nα-acetyl-(L)-tryptophan benzyl ester

Nα-acetyl-(L)-tryptophan benzyl ester

Conditions
ConditionsYield
With N-ethyl-N,N-diisopropylamine In N,N-dimethyl-formamide at 20℃; for 23h; Inert atmosphere;99%
N-AcTrp
1218-34-4

N-AcTrp

L-Tryptophan
73-22-3

L-Tryptophan

Conditions
ConditionsYield
With pepsin immobilized on terephthalaldehyde functionalized chitosan magnetic nanoparticle In acetonitrile at 20℃; for 48h; pH=2;98%
With hydrogenchloride; water
With sulfuric acid; water
With Aspergillus oryzae acylase relative rates;
sodium thiocyanide
540-72-7

sodium thiocyanide

acetic anhydride
108-24-7

acetic anhydride

N-AcTrp
1218-34-4

N-AcTrp

(S)-5-((1H-indol-3-yl)methyl)-1-acetyl-2-thioxoimidazolidin-4-one
182002-62-6

(S)-5-((1H-indol-3-yl)methyl)-1-acetyl-2-thioxoimidazolidin-4-one

Conditions
ConditionsYield
In acetic acid at 80 - 85℃; for 0.5h;95%
benzylamine
100-46-9

benzylamine

N-AcTrp
1218-34-4

N-AcTrp

Nα-acetyl-(L)-tryptophan benzyl ester

Nα-acetyl-(L)-tryptophan benzyl ester

Conditions
ConditionsYield
Stage #1: N-AcTrp With N-chlorobenzotriazole; triphenylphosphine In dichloromethane at 0 - 20℃; for 0.25h;
Stage #2: benzylamine With triethylamine at 20℃; for 1.83333h;
95%
trans-dihydroxo (2,3,6,7,12,13,16,17-octaethylporphyrinato)-tin(IV)
29008-64-8

trans-dihydroxo (2,3,6,7,12,13,16,17-octaethylporphyrinato)-tin(IV)

N-AcTrp
1218-34-4

N-AcTrp

trans-di(N-acetyl-L–tryptophanato)[2,3,6,7,12,13,16,17-octa-ethylporphyrinato]-tin(IV)

trans-di(N-acetyl-L–tryptophanato)[2,3,6,7,12,13,16,17-octa-ethylporphyrinato]-tin(IV)

Conditions
ConditionsYield
In chloroform for 12h; Reflux;92%
methyl (2S)-2-amino-3-phenylpropanoate hydrochloride
7524-50-7

methyl (2S)-2-amino-3-phenylpropanoate hydrochloride

N-AcTrp
1218-34-4

N-AcTrp

(S)-methyl 2-((S)-2-acetamido-3-(1H-indol-3-yl)propanmido)-3-phenyl propanoate

(S)-methyl 2-((S)-2-acetamido-3-(1H-indol-3-yl)propanmido)-3-phenyl propanoate

Conditions
ConditionsYield
Stage #1: methyl (2S)-2-amino-3-phenylpropanoate hydrochloride With potassium carbonate In water at 25℃; for 0.166667h;
Stage #2: N-AcTrp With O-(1H-benzotriazol-1-yl)-N,N,N',N'-tetramethyluronium hexafluorophosphate; N-ethyl-N,N-diisopropylamine In dichloromethane at 25℃; for 12h;
91%
Stage #1: N-AcTrp With benzotriazol-1-ol; O-(1H-benzotriazol-1-yl)-N,N,N',N'-tetramethyluronium hexafluorophosphate; triethylamine In dichloromethane at 20℃; for 0.5h; Schlenk technique;
Stage #2: methyl (2S)-2-amino-3-phenylpropanoate hydrochloride In dichloromethane Schlenk technique;
Stage #1: N-AcTrp With benzotriazol-1-ol; O-(1H-benzotriazol-1-yl)-N,N,N',N'-tetramethyluronium hexafluorophosphate; triethylamine In dichloromethane at 20℃; for 0.5h; Schlenk technique;
Stage #2: methyl (2S)-2-amino-3-phenylpropanoate hydrochloride In dichloromethane Schlenk technique;
trans-dihydroxo(meso-tetraphenylporphyrinato)tin(IV)
26334-89-4

trans-dihydroxo(meso-tetraphenylporphyrinato)tin(IV)

N-AcTrp
1218-34-4

N-AcTrp

trans-di(N-acetyl-L–tryptophanato)[5,10,15,20-tetraphenyl-porphyrinato]-tin(IV)

trans-di(N-acetyl-L–tryptophanato)[5,10,15,20-tetraphenyl-porphyrinato]-tin(IV)

Conditions
ConditionsYield
In chloroform for 12h; Reflux;91%
ethanol
64-17-5

ethanol

N-AcTrp
1218-34-4

N-AcTrp

N-acetyl-L-tryptophane ethyl ester
2382-80-1

N-acetyl-L-tryptophane ethyl ester

Conditions
ConditionsYield
lipoglycosylated α-chymotrypsin In chloroform at 30℃; or other solvents;90%
α-chymotrypsin In chloroform; water at 30℃; for 24h; phosphate buffer, pH 6.8;86%
α-chymotrypsin at 30℃; for 24h; Equilibrium constant; effect of water concentration, solvent, pH;78%
N-AcTrp
1218-34-4

N-AcTrp

butan-1-ol
71-36-3

butan-1-ol

acetyl-L-tryptophan n-butyl ester
2743-54-6

acetyl-L-tryptophan n-butyl ester

Conditions
ConditionsYield
With toluene-4-sulfonic acid a) 50 deg C, 0.5 h, b) RT, 4 h;90%
L-valine methylester hydrochloride
6306-52-1

L-valine methylester hydrochloride

N-AcTrp
1218-34-4

N-AcTrp

Ac-Trp-Val-OMe
248589-70-0

Ac-Trp-Val-OMe

Conditions
ConditionsYield
With O-(1H-benzotriazol-1-yl)-N,N,N',N'-tetramethyluronium hexafluorophosphate; N-ethyl-N,N-diisopropylamine In tetrahydrofuran at 20℃;89%
Stage #1: N-AcTrp With benzotriazol-1-ol; O-(1H-benzotriazol-1-yl)-N,N,N',N'-tetramethyluronium hexafluorophosphate; triethylamine In dichloromethane at 20℃; for 0.5h; Schlenk technique;
Stage #2: L-valine methylester hydrochloride In dichloromethane Schlenk technique;
Stage #1: N-AcTrp With benzotriazol-1-ol; O-(1H-benzotriazol-1-yl)-N,N,N',N'-tetramethyluronium hexafluorophosphate; triethylamine In dichloromethane at 20℃; for 0.5h; Schlenk technique;
Stage #2: L-valine methylester hydrochloride In dichloromethane Schlenk technique;
(S)-methyl 2-amino-4-(methylthio)butanoate hydrochloride
2491-18-1

(S)-methyl 2-amino-4-(methylthio)butanoate hydrochloride

N-AcTrp
1218-34-4

N-AcTrp

Ac-Trp-Met-OMe

Ac-Trp-Met-OMe

Conditions
ConditionsYield
Stage #1: (S)-methyl 2-amino-4-(methylthio)butanoate hydrochloride With potassium carbonate In water at 25℃; for 0.166667h;
Stage #2: N-AcTrp With O-(1H-benzotriazol-1-yl)-N,N,N',N'-tetramethyluronium hexafluorophosphate; N-ethyl-N,N-diisopropylamine In dichloromethane at 25℃; for 12h;
89%
Stage #1: N-AcTrp With benzotriazol-1-ol; O-(1H-benzotriazol-1-yl)-N,N,N',N'-tetramethyluronium hexafluorophosphate; triethylamine In dichloromethane at 20℃; for 0.5h; Schlenk technique;
Stage #2: (S)-methyl 2-amino-4-(methylthio)butanoate hydrochloride In dichloromethane Schlenk technique;
Stage #1: N-AcTrp With benzotriazol-1-ol; O-(1H-benzotriazol-1-yl)-N,N,N',N'-tetramethyluronium hexafluorophosphate; triethylamine In dichloromethane at 20℃; for 0.5h; Schlenk technique;
Stage #2: (S)-methyl 2-amino-4-(methylthio)butanoate hydrochloride In dichloromethane Schlenk technique;
O-Methyl (S)-prop-2-ynyl dithiocarbonate
123972-87-2

O-Methyl (S)-prop-2-ynyl dithiocarbonate

N-AcTrp
1218-34-4

N-AcTrp

N-acetyl-L-tryptophan methyl ester
2824-57-9, 16108-06-8, 36060-94-3

N-acetyl-L-tryptophan methyl ester

Conditions
ConditionsYield
In toluene Heating;87%
(R)-1-phenyl-ethyl-amine
3886-69-9

(R)-1-phenyl-ethyl-amine

N-AcTrp
1218-34-4

N-AcTrp

(S)-2-Acetylamino-3-(1H-indol-3-yl)-N-((R)-1-phenyl-ethyl)-propionamide

(S)-2-Acetylamino-3-(1H-indol-3-yl)-N-((R)-1-phenyl-ethyl)-propionamide

Conditions
ConditionsYield
With benzotriazol-1-ol; dicyclohexyl-carbodiimide In N,N-dimethyl-formamide 1.) 0 deg C, 2 h, 2.) r.t., overnight;87%
(S)-1-phenyl-ethylamine
2627-86-3

(S)-1-phenyl-ethylamine

N-AcTrp
1218-34-4

N-AcTrp

(S)-2-Acetylamino-3-(1H-indol-3-yl)-N-((S)-1-phenyl-ethyl)-propionamide

(S)-2-Acetylamino-3-(1H-indol-3-yl)-N-((S)-1-phenyl-ethyl)-propionamide

Conditions
ConditionsYield
With benzotriazol-1-ol; dicyclohexyl-carbodiimide In N,N-dimethyl-formamide 1.) 0 deg C, 2 h, 2.) r.t., overnight;85%
[(η6-phenylbutyric acid)tris(acetone)ruthenium(II)] triflate

[(η6-phenylbutyric acid)tris(acetone)ruthenium(II)] triflate

N-AcTrp
1218-34-4

N-AcTrp

[(η6-phenylbutyric acid)(η6-N-acetyltriptophane)ruthenium(II)] triflate

[(η6-phenylbutyric acid)(η6-N-acetyltriptophane)ruthenium(II)] triflate

Conditions
ConditionsYield
In trifluoroacetic acid Ar, stirred at 50°C for 3 h; concd., pptd. (diethyl ether), washed (methanol/diethyl ether), dried (vac.); elem. anal.;84%
S-(1-butyn-3-yl)-O-methyl xanthate

S-(1-butyn-3-yl)-O-methyl xanthate

N-AcTrp
1218-34-4

N-AcTrp

N-acetyl-L-tryptophan methyl ester
2824-57-9, 16108-06-8, 36060-94-3

N-acetyl-L-tryptophan methyl ester

Conditions
ConditionsYield
In toluene Heating;81%
(R)-(+)-N,α-dimethylbenzylamine
5933-40-4

(R)-(+)-N,α-dimethylbenzylamine

N-AcTrp
1218-34-4

N-AcTrp

(S)-2-Acetylamino-3-(1H-indol-3-yl)-N-methyl-N-((R)-1-phenyl-ethyl)-propionamide

(S)-2-Acetylamino-3-(1H-indol-3-yl)-N-methyl-N-((R)-1-phenyl-ethyl)-propionamide

Conditions
ConditionsYield
With benzotriazol-1-ol; dicyclohexyl-carbodiimide In N,N-dimethyl-formamide 1.) 0 deg C, 2 h, 2.) r.t., overnight;80%
[Ru(η(6)-cymene)(acetone)3](CF3SO3)2

[Ru(η(6)-cymene)(acetone)3](CF3SO3)2

N-AcTrp
1218-34-4

N-AcTrp

Ru(CH3C6H4C3H7)(CH3CONHCH(CH2C8H6N)CO2H)(2+)*2CF3SO3(1-)=[Ru(CH3C6H4C3H7)(CH3CONHCH(CH2C8H6N)CO2H)](CF3SO3)2

Ru(CH3C6H4C3H7)(CH3CONHCH(CH2C8H6N)CO2H)(2+)*2CF3SO3(1-)=[Ru(CH3C6H4C3H7)(CH3CONHCH(CH2C8H6N)CO2H)](CF3SO3)2

Conditions
ConditionsYield
In trifluoroacetic acid (argon); stirring (room temp., 4 h); pptn. with Et2O, washing, drying (vac.); elem. anal.;80%
N-AcTrp
1218-34-4

N-AcTrp

N-acetyl-L-tryptophan methyl ester
2824-57-9, 16108-06-8, 36060-94-3

N-acetyl-L-tryptophan methyl ester

Conditions
ConditionsYield
In methanol; diethyl ether at 0℃;79%
Dithiocarbonic acid O-(3-methyl-oxetan-3-ylmethyl) ester S-prop-2-ynyl ester

Dithiocarbonic acid O-(3-methyl-oxetan-3-ylmethyl) ester S-prop-2-ynyl ester

N-AcTrp
1218-34-4

N-AcTrp

(S)-2-Acetylamino-3-(1H-indol-3-yl)-propionic acid 3-methyl-oxetan-3-ylmethyl ester

(S)-2-Acetylamino-3-(1H-indol-3-yl)-propionic acid 3-methyl-oxetan-3-ylmethyl ester

Conditions
ConditionsYield
In toluene Heating;79%
methyl (L)-leucinate hydrochloride
7517-19-3

methyl (L)-leucinate hydrochloride

N-AcTrp
1218-34-4

N-AcTrp

(S)-methyl 2-((S)-2-acetamido-3-(1H-indol-3-yl)propanamido)-4-methyl pentanoate

(S)-methyl 2-((S)-2-acetamido-3-(1H-indol-3-yl)propanamido)-4-methyl pentanoate

Conditions
ConditionsYield
Stage #1: methyl (L)-leucinate hydrochloride With potassium carbonate In water at 25℃; for 0.166667h;
Stage #2: N-AcTrp With O-(1H-benzotriazol-1-yl)-N,N,N',N'-tetramethyluronium hexafluorophosphate; N-ethyl-N,N-diisopropylamine In dichloromethane at 25℃; for 12h;
79%
Stage #1: N-AcTrp With benzotriazol-1-ol; O-(1H-benzotriazol-1-yl)-N,N,N',N'-tetramethyluronium hexafluorophosphate; triethylamine In dichloromethane at 20℃; for 0.5h; Schlenk technique;
Stage #2: methyl (L)-leucinate hydrochloride In dichloromethane Schlenk technique;
Stage #1: N-AcTrp With benzotriazol-1-ol; O-(1H-benzotriazol-1-yl)-N,N,N',N'-tetramethyluronium hexafluorophosphate; triethylamine In dichloromethane at 20℃; for 0.5h; Schlenk technique;
Stage #2: methyl (L)-leucinate hydrochloride In dichloromethane Schlenk technique;
(5-(3-(trifluoromethyl)-3H-diazirin-3-yl)pyridin-2-yl)methanol

(5-(3-(trifluoromethyl)-3H-diazirin-3-yl)pyridin-2-yl)methanol

N-AcTrp
1218-34-4

N-AcTrp

(S)-(5-(3-(trifluoromethyl)-3H-diazirin-3-yl)pyridin-2-yl)methyl 2-acetamido-3-(1H-indol-3-yl)propanoate

(S)-(5-(3-(trifluoromethyl)-3H-diazirin-3-yl)pyridin-2-yl)methyl 2-acetamido-3-(1H-indol-3-yl)propanoate

Conditions
ConditionsYield
With dmap; 1-ethyl-(3-(3-dimethylamino)propyl)-carbodiimide hydrochloride In N,N-dimethyl-formamide at 21℃; for 16h; Inert atmosphere;77%
With dmap; 1-ethyl-(3-(3-dimethylamino)propyl)-carbodiimide hydrochloride In N,N-dimethyl-formamide at 21℃; for 16h; Inert atmosphere;77%
N-methyl-N-[(S)-1-phenylethyl]amine
19131-99-8

N-methyl-N-[(S)-1-phenylethyl]amine

N-AcTrp
1218-34-4

N-AcTrp

(S)-2-Acetylamino-3-(1H-indol-3-yl)-N-methyl-N-((S)-1-phenyl-ethyl)-propionamide

(S)-2-Acetylamino-3-(1H-indol-3-yl)-N-methyl-N-((S)-1-phenyl-ethyl)-propionamide

Conditions
ConditionsYield
With benzotriazol-1-ol; dicyclohexyl-carbodiimide In N,N-dimethyl-formamide 1.) 0 deg C, 2 h, 2.) r.t., overnight;76%
2,6-dimethylaniline
87-62-7

2,6-dimethylaniline

N-AcTrp
1218-34-4

N-AcTrp

(S)-2-Acetylamino-N-(2,6-dimethyl-phenyl)-3-(1H-indol-3-yl)-propionamide

(S)-2-Acetylamino-N-(2,6-dimethyl-phenyl)-3-(1H-indol-3-yl)-propionamide

Conditions
ConditionsYield
With benzotriazol-1-ol; dicyclohexyl-carbodiimide In N,N-dimethyl-formamide 1.) 0 deg C, 2 h, 2.) r.t., overnight;75%
hexakis-(6-bromo-6-deoxy)-α-cyclodextrin
53784-82-0

hexakis-(6-bromo-6-deoxy)-α-cyclodextrin

N-AcTrp
1218-34-4

N-AcTrp

hexakis-[6-O-(N-acetyl-L-tryptophanyl)]-α-cyclodextrin
1320346-76-6

hexakis-[6-O-(N-acetyl-L-tryptophanyl)]-α-cyclodextrin

Conditions
ConditionsYield
With 1,8-diazabicyclo[5.4.0]undec-7-ene In N,N-dimethyl-formamide at 70 - 80℃; for 12h;72%
2,6-diethylaniline
579-66-8

2,6-diethylaniline

N-AcTrp
1218-34-4

N-AcTrp

(S)-2-Acetylamino-N-(2,6-diethyl-phenyl)-3-(1H-indol-3-yl)-propionamide

(S)-2-Acetylamino-N-(2,6-diethyl-phenyl)-3-(1H-indol-3-yl)-propionamide

Conditions
ConditionsYield
With benzotriazol-1-ol; dicyclohexyl-carbodiimide In N,N-dimethyl-formamide 1.) 0 deg C, 2 h, 2.) r.t., overnight;70%

1218-34-4Relevant articles and documents

Biosynthesis of violacein: Origins of hydrogen, nitrogen and oxygen atoms in the 2-pyrrolidone nucleus

Hoshino,Takano,Hori,Ogasawara

, p. 2733 - 2741 (1987)

-

A fundamental study of amadori rearrangement products in reducing sugar-amino acid model system by electrospray ionization mass spectrometry and computation

Zhang,Ruan,Wang,Ruan,Shao,Aalhus,Juárez

, p. 2941 - 2944 (2014)

It is crucial to characterize Amadori rearrangement products (ARPs) formed in the early stage of Maillard reaction, one of the most important modifications in food science. We setup a reaction model system using six selected amino acids (arginine, asparagines, glutamine, histamine, lysine and tryptophan) and their N-terminal acetylated forms with different reducing sugars for a fundamental study of Amadori rearrangement products. The effects on forming Amadori rearrangement products were studied by using electrospray ionization mass spectrometry (ESI-MS). The reaction rate was affected by reaction temperature, reaction time, property of sugars and amino acids and the fragmentation mechanism of Amadori rearrangement products was illustrated by tandem MS (MS2) with collision-induced dissociation. The proposed fragmentation mechanism of Amadori rearrangement products in MS2 was provided based on MS2 data and it was supported by their computational data of density functional theory (DFT) at the B3LYP/6-31++G(d,p) level.

Comparison of HNO reactivity with tryptophan and cysteine in small peptides

Keceli, Gizem,Moore, Cathy D.,Toscano, John P.

, p. 3710 - 3713 (2014)

Recent discoveries of important pharmacological properties have drawn attention to the reactivity of HNO (azanone, nitroxyl) with biologically relevant substrates. Apart from its role in thiol oxidation, HNO has been reported to have nitrosative properties, for example, with tryptophan resulting in N-nitrosotryptophan formation. We have investigated the reactivity of HNO with tryptophan and small peptides containing either tryptophan or both a tryptophan and a cysteine residue. Our results point to the more reactive nature of cysteine towards HNO compared with tryptophan.

The biosynthetic pathway of crucifer phytoalexins and phytoanticipins: De novo incorporation of deuterated tryptophans and quasi-natural compounds

Pedras, M. Soledade C.,Okinyo-Owiti, Denis P.,Thoms, Ken,Adio, Adewale M.

, p. 1129 - 1138 (2009)

Although several biosynthetic intermediates in pathways to cruciferous phytoalexins and phytoanticipins are common, questions regarding the introduction of substituents at N-1 of the indole moiety remain unanswered. Toward this end, we investigated the potential incorporations of several perdeuterated d- and l-1′-methoxytryptophans, d- and l-tryptophans and other indol-3-yl derivatives into pertinent phytoalexins and phytoanticipins (indolyl glucosinolates) produced in rutabaga (Brassica napus L. ssp. rapifera) roots. In addition, we probed the potential transformations of quasi-natural compounds, these being analogues of biosynthetic intermediates that might lead to "quasi-natural" products (products similar to natural products but not produced under natural conditions). No detectable incorporations of deuterium labeled 1′-methoxytryptophans into phytoalexins or glucobrassicin were detected. l-tryptophan was incorporated in a higher percentage than d-tryptophan into both phytoalexins and phytoanticipins. However, in the case of the phytoalexin rapalexin A, both d- and l-tryptophan were incorporated to the same extent. Furthermore, the transformations of both 1′-methylindolyl-3′-acetaldoxime and 1′-methylindolyl-3′-acetothiohydroxamic acid (quasi-natural products) into 1′-methylglucobrassicin but not into phytoalexins suggested that post-aldoxime enzymes in the biosynthetic pathway of indolyl glucosinolates are not substrate-specific. Hence, it would appear that the 1-methoxy substituent of the indole moiety is introduced downstream from tryptophan and that the post-aldoxime enzymes of the glucosinolate pathway are different from the enzymes of the phytoalexin pathway. A higher substrate specificity of some enzymes of the phytoalexin pathway might explain the relatively lower structural diversity among phytoalexins than among glucosinolates.

Studies on acylase activity and microorganisms. VIII. Enzymatic hydrolysis of 6-N-benzoyl-L-lysine.

KAMEDA,TOYOURA,KIMURA,MATSUI

, p. 394 - 395 (1958)

-

Hydrogen/deuterium exchange of cross-linkable α-amino acid derivatives in deuterated triflic acid

Wang, Lei,Murai, Yuta,Yoshida, Takuma,Okamoto, Masashi,Masuda, Katsuyoshi,Sakihama, Yasuko,Hashidoko, Yasuyuki,Hatanaka, Yasumaru,Hashimoto, Makoto

, p. 1129 - 1134 (2014)

In this paper we report here a hydrogen/deuterium exchange (H/D exchange) of cross-linkable α-amino acid derivatives with deuterated trifluoromethanesulfonic acid (TfOD). H/D exchange with TfOD was easily applied to o-catechol containing phenylalanine (DOPA) within an hour. A partial H/D exchange was observed for trifluoromethyldiazirinyl (TFMD) phenylalanine derivatives. N-Acetyl-protected natural aromatic α-amino acids (Tyr and Trp) were more effective in H/D exchange than unprotected ones. The N-acetylated TFMD phenylalanine derivative afforded slightly higher H/D exchange than unprotected derivatives. An effective post-deuteration method for cross-linkable α-amino acid derivatives will be useful for the analysis of biological functions of bioactive peptides and proteins by mass spectrometry.

Catecholamine-induced release of nitric oxide from N-nitrosotryptophan derivatives: A non-enzymatic method for catecholamine oxidation

Kytzia, Anna,Korth, Hans-Gert,De Groot, Herbert,Kirsch, Michael

, p. 257 - 267 (2006)

In recent years, interest in the physiological functions of S-nitrosothiols has strongly increased owing to the potential of these compounds to release nitric oxide. In contrast, little is known about similar functions of N-nitrosated (N-terminal-blocked) tryptophan derivatives, which can be also formed at physiological pH. Utilizing N-acetyl-N-nitrosotryptophan (NANT) and N-nitrosomelatonin (NOMela) as model compounds, we have studied their reaction with catechol and catecholamines such as epinephrine and dopamine. In these reactions, NANT was quantitatively converted to N-acetyltryptophan (NAT), and nitric oxide was identified as a volatile product. During this process, ortho-semiquinone-type radical anions deriving from catechol and dopamine, were detected by ESR spectrometry. The catechol radical concentration was about eight times higher under normoxia than under hypoxia and a similar relationship was found for the decay rates of NANT under these conditions. An epinephrine-derived oxidation product, namely adrenochrome, but not a catechol-derived one, was identified. These observations strongly indicate that N-nitrosotryptophan derivatives transfer their nitroso-function to an oxygen atom of the catecholamines, and that the so-formed intermediary aryl nitrite may decompose homolytically with release of nitric oxide, in addition to a competing hydrolysis reaction to yield nitrite and the corresponding catechol. These conclusions were supported by quantum chemical calculations performed at the CBS-QB3 level of theory. Since nitric oxide is non-enzymatically released from N-nitrosotryptophan derivatives on reaction with catecholamines, there might be a possibility for the development of epinephrine-antagonizing drugs in illnesses like hypertension and pheochromocytoma. The Royal Society of Chemistry 2006.

-

Snyder,MacDonald

, p. 1257,1258 (1955)

-

Tryptophan derivative and application thereof

-

Paragraph 0192-0194, (2020/05/30)

The invention discloses a tryptophan derivative or salt acceptable in feed, a stereoisomer, a tautomer, a solvate and a prodrug molecule of the tryptophan derivative. The tryptophan derivative has a structure shown in a formula (I). The tryptophan derivative as shown in the formula (I) and acceptable salt, stereoisomer, tautomer, solvate and prodrug molecules thereof in the feed all show more stable physicochemical properties than tryptophan in a raw material high thermal stability test and a normal temperature stability test of the feed. The content change of the tryptophan derivative does not exceed the acceptable change range of the feed additive or the feed in the test period; moreover, the compounds can effectively improve the growth of animals, feed conversion and other production performances, even have more excellent improvement effects than tryptophan, and can be used as animal feed additives or used for preparing animal feed additives or animal feeds.

Synthesis and evaluation of oxindoles as promising inhibitors of the immunosuppressive enzyme indoleamine 2,3-dioxygenase 1

Paul, Saurav,Roy, Ashalata,Deka, Suman Jyoti,Panda, Subhankar,Srivastava, Gopal Narayan,Trivedi, Vishal,Manna, Debasis

, p. 1640 - 1654 (2017/08/22)

Indoleamine 2,3-dioxygenase 1 (IDO1) is considered as an important therapeutic target for the treatment of cancer, chronic infections and other diseases that are associated with immune suppression. Recent developments in understanding the catalytic mechanism of the IDO1 enzyme revealed that conversion of l-tryptophan (l-Trp) to N-formylkynurenine proceeded through an epoxide intermediate state. Accordingly, we synthesized a series of 3-substituted oxindoles from l-Trp, tryptamine and isatin. Compounds with C3-substituted oxindole moieties showed moderate inhibitory activity against the purified human IDO1 enzyme. Their optimization led to the identification of potent compounds, 6, 22, 23 and 25 (IC50 = 0.19 to 0.62 μM), which are competitive inhibitors of IDO1 with respect to l-Trp. These potent compounds also showed IDO1 inhibition potencies in the low-micromolar range (IC50 = 0.33-0.49 μM) in MDA-MB-231 cells. The cytotoxicity of these potent compounds was trivial in different model cancer (MDA-MB-231, A549 and HeLa) cells and macrophage (J774A.1) cells. Stronger selectivity for the IDO1 enzyme (124 to 210-fold) over the tryptophan 2,3-dioxygenase (TDO) enzyme was also observed for these compounds. These results suggest that the oxindole moiety of the compounds could mimic the epoxide intermediate state of l-Trp. Therefore, the structural simplicity and low-micromolar inhibition potencies of these 3-substituted oxindoles make them quite attractive for further investigation of IDO1 function and immunotherapeutic applications.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1

What can I do for you?
Get Best Price

Get Best Price for 1218-34-4